UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004094
Receipt number R000004889
Scientific Title Exploratory trials evaluating the pharmacokinetics of Quinidine and Verapamil after oral administration in healthy male subjects
Date of disclosure of the study information 2010/09/01
Last modified on 2010/10/26 14:21:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploratory trials evaluating the pharmacokinetics of Quinidine and Verapamil after oral administration in healthy male subjects

Acronym

Exploratory trials evaluating the pharmacokinetics of Quinidine and Verapamil after oral administration in healthy male subjects

Scientific Title

Exploratory trials evaluating the pharmacokinetics of Quinidine and Verapamil after oral administration in healthy male subjects

Scientific Title:Acronym

Exploratory trials evaluating the pharmacokinetics of Quinidine and Verapamil after oral administration in healthy male subjects

Region

Japan


Condition

Condition

Healthy male subjects

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the role of MDR1 and CYP3A4 in intestinal absorption of Quinidine and Verapamil.

Basic objectives2

Pharmacokinetics

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Pharmacokinetics of Quinidine and Verapamil

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Quinidine,Verapamil,Fexofenadine,Midazolam,Celiprolol and Itraconazole

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

45 years-old >=

Gender

Male

Key inclusion criteria

Key criteria to be considered for this study:
(1)Healthy male subjects
(2)The subject is capable of giving written consent prior to screening.
(3)The subject aged between 20 and 45 years inclusive at screening.
(4)The subject has a body mass index in the range of 17.6 to 28.0 kg/m2.
(5)The subject is able to abstain from smoking during the hospitalization.

Key exclusion criteria

The following subjects shall be excluded from this study:
(1)The subject has any medical history that is not considered as eligible for
inclusion in this study by the investigator.
(2)The subject has the disease which needs a treatment at present.
(3)The subject is currently participating in another clinical study and is exposed to an investigational drug.
(4) The subject has any medical history of known allergy or hypersensitivity to quinidine, verapamil, fexofenadine, midazolam, celiprorol and itraconazole.
(5) The subject has donated whole blood">400mL" within the previous 3 months or ">200mL" within the previous 1 month, and components of blood(apheresis) within the previous 2 weeks.
(6) The subject has hypersensitivity to any drugs and foods.
(7) The subject has a history or current conditions of drug abuse or alcoholism.
(8)The subject is positive for HBs antigen, syphilis, HCV antibody, HIV antigen/antibody.
(9)The subject has any clinically relevant abnormality on vital sign, clinical laboratory test, ECG and medical examination. (The subject who admitted participation in this study in the judgement of investigator excludes.)
(10)Any subjects considered to be unsuitable for the study by the reseacher.

Target sample size

8


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tetsuya Komatsuzaki

Organization

Tsukuba International Clinical Pharmacology Clinic

Division name

medical office

Zip code


Address

1-21-16 Kannondai Tsukuba city,Ibaraki,JAPAN

TEL

029-839-1150

Email



Public contact

Name of contact person

1st name
Middle name
Last name Masaaki Mochii

Organization

Tsukuba International Clinical Pharmacology Clinic

Division name

Clinical Trial Project Office

Zip code


Address

1-21-16 Kannondai Tsukuba city,Ibaraki,JAPAN

TEL

029-839-1150

Homepage URL


Email

m-mochii@tsukuba-icp.jp


Sponsor or person

Institute

APDD

Institute

Department

Personal name



Funding Source

Organization

APDD

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 09 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 07 Month 29 Day

Date of IRB


Anticipated trial start date

2010 Year 09 Month 01 Day

Last follow-up date

2010 Year 11 Month 01 Day

Date of closure to data entry

2010 Year 12 Month 01 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 08 Month 24 Day

Last modified on

2010 Year 10 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004889


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name